Skip to main content
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. — Investor Relations & Filings

Ticker · CADL ISIN · US1374041093 US Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2021-07-27 Director's Dealing
Country US United States of America
Listing US CADL

About Candel Therapeutics, Inc.

https://www.candeltx.com/

Candel Therapeutics, Inc. is a company developing viral immunotherapies designed to activate a patient's immune system to fight cancer. Its approach utilizes two main platforms based on engineered adenovirus and Herpes Simplex Virus (HSV). These investigational, off-the-shelf therapies are administered directly into tumors to induce immunogenic cell death. This process is intended to stimulate a personalized, systemic, and durable anti-tumor response specific to the individual's cancer. The company aims to create treatments that are both efficacious and well-tolerated for patients across various disease stages.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2021-07-27 English
FORM 3 SUBMISSION
Director's Dealing
2021-07-27 English
FORM 3 SUBMISSION
Director's Dealing
2021-07-27 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 95% confidence The document is a letter from underwriters requesting acceleration of the effective date of a Registration Statement on Form S-1. It references regulatory rules under the Securities Act of 1933 and the Securities Exchange Act of 1934. The content is a formal request related to the registration process for a securities offering, not a financial report or earnings release. The document length is short (2404 characters) and it is clearly an announcement/request letter rather than a report containing financial data or analysis. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as registration statements and underwriter communications.
2021-07-26 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-1. It is a formal correspondence related to the registration process for securities, specifically requesting the SEC to expedite the effectiveness of the registration statement. The document does not contain financial data, report content, or detailed disclosures but is rather an administrative request related to the registration process. This type of document is best classified under Regulatory Filings (RNS) as it is a regulatory communication that does not fit into other specific report categories.
2021-07-26 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A Registration Statement Amendment No. 3 filed with the SEC by Candel Therapeutics, Inc. The S-1 form is used for initial public offerings (IPOs) to register securities with the SEC. The text includes detailed information about the offering, company overview, risk factors, management discussion, financial data summary, and underwriting details. It is not an annual report, earnings release, or any other financial report but a registration statement for a capital raising event. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement text, not just an announcement or a certification, confirming it is the actual filing. Hence, the classification is CAP with high confidence.
2021-07-26 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.